# BBIO catalysts: BridgeBio Pharma, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/bbio/catalysts

> BridgeBio Pharma, Inc. (BBIO) has 6 upcoming catalysts. The next is the ribitol PDUFA date, November 27, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, year only, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for BBIO?

BridgeBio Pharma, Inc. (BBIO) has 6 upcoming catalysts. The next is the ribitol PDUFA date, November 27, 2026. Press release filed with the SEC (EX-99): "- BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, with Priority Review." [Calendar and source filings](https://sec-api.dev/companies/bbio/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001743881-26-000033, https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm (retrieved 2026-11-12). Last confirmed 2026-10-29. Cite: https://sec-api.dev/companies/bbio/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | BridgeBio Pharma, Inc. |
| Ticker | BBIO (Nasdaq) |
| SEC CIK | 1743881 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/bbio |

## Cash runway

Cash $1.54B as of 2026-09-30; quarterly burn $44.2M; about 104.5 months of runway at that rate (XBRL company facts, accession 0001743881-26-000034).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 12, 2024 | [BridgeBio Pharma, Inc. earnings report](https://sec-api.dev/companies/bbio/catalysts) | BBIO |  | completed | "BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000095017024124576/bbio-ex99_1.htm)) |
| November 22, 2024 | [Beyonttra (beyonttra) FDA approval](https://sec-api.dev/pdufa/beyonttra) | BBIO |  | completed, approved | ""Business" of this Annual Report on Form 10-K, we currently have one commercial product, AttrubyTM that received FDA approval on November 22, 2024 and Beyonttra that received approval from the EC on February 10, 2025, and multiple product candidates in late-stage development." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1743881/000095017025024119/bbio-20241231.htm)) |
| November 22, 2024 | [Attruby (acoramidis) FDA approval](https://sec-api.dev/pdufa/acoramidis) | BBIO | To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis | completed, approved | "Attruby \| acoramidis \| 11/22/2024 \| To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosisDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| November 29, 2024 | [BridgeBio Pharma, Inc. PDUFA date](https://sec-api.dev/companies/bbio/catalysts) | BBIO |  | scheduled | "November 29, 2024 PDUFA date" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000095017024124576/bbio-ex99_1.htm)) |
| November 29, 2024 | [Attruby (acoramidis) PDUFA date](https://sec-api.dev/pdufa/acoramidis) | BBIO |  | completed, approved | "Based on the positive results from ATTRibute-CM, BridgeBio filed a new drug application (NDA) to the FDA, which has been accepted with a PDUFA action date of November 29, 2024, and the late cycle meeting with the FDA has been completed." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000095017024124576/bbio-ex99_1.htm)) |
| 1H 2025 | [Attruby (acoramidis) trial start](https://sec-api.dev/pdufa/acoramidis) | BBIO |  | scheduled | "- Well-financed to launch Attruby and read out major market Phase 3 trials: $406M in cash as of last quarter, received $500M upon acoramidis FDA approval from royalty facility, and anticipate $105M in regulatory milestones in 1H 2025 from acoramidis Europe and Japan approvals" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000114036125000943/ef20041481_ex99-1.htm)) |
| 2025 | [Ribitol topline data readout](https://sec-api.dev/pdufa/ribitol) | BBIO | LGMD2I/R9, with topline data readout | scheduled | "BridgeBio completed enrollment of FORTIFY, the Company's Phase 3 registrational study of BBP-418 in individuals with LGMD2I/R9, with topline data readout from the interim analysis expected in 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000095017024124576/bbio-ex99_1.htm)) |
| February 20, 2025 | [Attruby (acoramidis) earnings report](https://sec-api.dev/pdufa/acoramidis) | BBIO |  | completed | "PALO ALTO, CA - February 20, 2025 - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases announced today its financial results for the fourth quarter and full year ended December 31, 2024, and provided an update on Attruby's commercial progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000095017025023741/bbio-ex99_1.htm)) |
| April 29, 2025 | [Attruby (acoramidis) earnings report](https://sec-api.dev/pdufa/acoramidis) | BBIO |  | completed | "PALO ALTO, CA - April 29, 2025 - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided an update on the Company's revenue, commercial progress of Attruby, and key late-stage pipeline highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000095017025060085/bbio-ex99_1.htm)) |
| 2H 2025 | [BridgeBio Pharma, Inc. topline data readout](https://sec-api.dev/companies/bbio/catalysts) | BBIO |  | scheduled | "BridgeBio expects last participant - last visit and topline readout of the interim analysis cohort in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000095017025060085/bbio-ex99_1.htm)) |
| August 5, 2025 | [BridgeBio Pharma, Inc. earnings report](https://sec-api.dev/companies/bbio/catalysts) | BBIO |  | completed | "PALO ALTO, CA - August 5, 2025 - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced its financial results for the second quarter ended June 30, 2025, and provided business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000095017025102985/bbio-ex99_1.htm)) |
| Oct 2025 | [Ribitol topline data readout](https://sec-api.dev/pdufa/ribitol) | BBIO |  | completed, met | "•Positive Phase 3 results for BBP-418 in LGMD2I/R9: In October 2025, we presented Topline data from the Phase 3 FORTIFY study showed BBP-418 achieved its primary and key secondary endpoints in limb-girdle muscular dystrophy type 2I/R9." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000009/bbio-20251231.htm)) |
| October 29, 2025 | [Encaleret topline data readout](https://sec-api.dev/pdufa/encaleret) | BBIO |  | completed, positive | "PALO ALTO, CA - October 29, 2025 - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced positive topline results from" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000114036125039705/ef20057894_ex99-1.htm)) |
| October 29, 2025 | [BridgeBio Pharma, Inc. earnings report](https://sec-api.dev/companies/bbio/catalysts) | BBIO |  | completed | "PALO ALTO, CA - October 29, 2025 - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced its financial results for the third quarter ended September 30, 2025, and provided business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/bbio-20250930xex991.htm)) |
| Q1 2026 | [BridgeBio Pharma, Inc. topline data readout](https://sec-api.dev/companies/bbio/catalysts) | BBIO |  | scheduled | "Last participant last visit completed; Topline expected Q1 2026 Pivotal Phase 3" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000114036126000971/ef20062706_ex99-2.htm)) |
| Q1 2026 | [Encaleret trial start](https://sec-api.dev/pdufa/encaleret) | BBIO | chronic hypoparathyroidism in 2026 | scheduled | "•The Company plans to initiate a registrational clinical trial of encaleret in pediatric ADH1 in the first quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/bbio-20250930xex991.htm)) |
| 1H 2026 | [Encaleret NDA/BLA submission](https://sec-api.dev/pdufa/encaleret) | BBIO | ADH1, the efficacy, safety | scheduled | "These forward-looking statements, including express and implied statements relating to the Phase 3 topline results for encaleret in patients with ADH1, the efficacy, safety and the clinical and therapeutic potential of encaleret, our plans to submit a New Drug Application for encaleret to the FDA in the first half of 2026, and to apply for Marketing Authorization Application to the EMA; our plans to initiate registrational studies of encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026, and the statements regarding the potential clinical benefits of encaleret for patients in the quotes of Dr. Mannstadt, Ms." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000114036125039705/ef20057894_ex99-1.htm)) |
| 1H 2026 | [Ribitol NDA/BLA submission](https://sec-api.dev/pdufa/ribitol) | BBIO |  | scheduled | "the topline results from FORTIFY, the Phase 3 clinical trial for BBP-418 for LGMD2I/R9 and the Company's plan to submit a New Drug Application for BBP-418 to the FDA in the first half of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/bbio-20250930xex991.htm)) |
| early 2026 | [TRUSELTIQ® (infigratinib) topline data readout](https://sec-api.dev/pdufa/infigratinib) | BBIO |  | scheduled | "•BridgeBio expects topline results of PROPEL 3 in early 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/bbio-20250930xex991.htm)) |
| February 12, 2026 | [TRUSELTIQ® (infigratinib) topline data readout](https://sec-api.dev/pdufa/infigratinib) | BBIO |  | completed, met | "On February 12, 2026, we reported positive Phase 3 Topline results from our PROPEL 3 study for oral infigratinib with the first statistically significant improvements in body proportionality in achondroplasia." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000009/bbio-20251231.htm)) |
| February 24, 2026 | [Attruby (acoramidis) earnings report](https://sec-api.dev/pdufa/acoramidis) | BBIO |  | completed | "PALO ALTO, Calif., February 24, 2026 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on Attruby's commercial progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000008/bbio-20251231xex9911.htm)) |
| March 30, 2026 | [Ribitol NDA/BLA submission](https://sec-api.dev/pdufa/ribitol) | BBIO |  | completed | "•On March 30, 2026, we submitted our NDA to the FDA for oral BBP-418 for the treatment of LGMD2I/R9." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000034/bbio-20260930.htm)) |
| May 6, 2026 | [Attruby (acoramidis) earnings report](https://sec-api.dev/pdufa/acoramidis) | BBIO |  | completed | "PALO ALTO, Calif., May 7, 2026 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the first quarter ended March 31, 2026, and provided an update on Attruby's commercial progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000018/bbio-2026331xex991.htm)) |
| May 27, 2026 | [Ribitol NDA/BLA acceptance](https://sec-api.dev/pdufa/ribitol) | BBIO |  | completed | "PALO ALTO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) with Priority" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/ef20074977_ex99-1.htm)) |
| 2H 2026 | [Encaleret trial start](https://sec-api.dev/pdufa/encaleret) | BBIO |  | scheduled | "•The Company also plans to initiate RECLAIM-HP, a Phase 3 study of encaleret in chronic hypoparathyroidism in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000008/bbio-20251231xex9911.htm)) |
| Q3 2026 | [TRUSELTIQ® (infigratinib) NDA/BLA submission](https://sec-api.dev/pdufa/infigratinib) | BBIO | achondroplasia, the efficacy, safety | scheduled | "•The Company intends to submit an NDA to the FDA in the third quarter of 2026, and an MAA to the EMA in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000018/bbio-2026331xex991.htm)) |
| July 22, 2026 | [Encaleret NDA/BLA acceptance](https://sec-api.dev/pdufa/encaleret) | BBIO | individuals living with autosomal dominant hypocalcemia type 1 | completed | "PALO ALTO, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) for encaleret for the treatment of individuals living with autosomal dominant hypocalcemia type 1 (ADH1)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000114036126029291/ef20078442_ex99-1.htm)) |
| August 4, 2026 | [TRUSELTIQ® (infigratinib) NDA/BLA submission](https://sec-api.dev/pdufa/infigratinib) | BBIO |  | completed | "•On August 4, 2026, we submitted our NDA to the FDA for low-dose infigratinib for achondroplasia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000034/bbio-20260930.htm)) |
| August 10, 2026 | [Attruby (acoramidis) earnings report](https://sec-api.dev/pdufa/acoramidis) | BBIO |  | completed | "PALO ALTO, Calif., August 10, 2026 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the second quarter ended June 30, 2026, and provided an update on Attruby's commercial progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260630xex991.htm)) |
| late 2026 | [Encaleret NDA/BLA submission](https://sec-api.dev/pdufa/encaleret) | BBIO |  | scheduled | "-On track for a 1H 2026 NDA submission following positive Phase 3 CALIBRATE results for encaleret in ADH1 and successful completion of a pre-NDA meeting with FDA; U.S. launch anticipated in late 2026/early 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000008/bbio-20251231xex9911.htm)) |
| late 2026 | [Ribitol NDA/BLA submission](https://sec-api.dev/pdufa/ribitol) | BBIO |  | scheduled | "-Positive interim Phase 3 FORTIFY results for BBP-418 in LGMD2I/R9 demonstrated a statistically significant and clinically meaningful 2.6-point NSAD improvement versus placebo at 12 months; FDA recommended pursuing traditional approval, supporting a planned 1H 2026 NDA submission and a U.S. launch anticipated in late 2026/early 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000008/bbio-20251231xex9911.htm)) |
| October 6, 2026 | [TRUSELTIQ® (infigratinib) NDA/BLA acceptance](https://sec-api.dev/pdufa/infigratinib) | BBIO | children with achondroplasia | completed | "PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) with Priority Review for oral infigratinib for the treatment of children with achondroplasia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000114036126039334/ef20083591_ex99-1.htm)) |
| October 29, 2026 | [Attruby (acoramidis) earnings report](https://sec-api.dev/pdufa/acoramidis) | BBIO |  | completed | "PALO ALTO, Calif., October 29, 2026 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the third quarter ended September 30, 2026, and provided an update on Attruby's commercial progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm)) |
| November 27, 2026 | [Ribitol PDUFA date](https://sec-api.dev/pdufa/ribitol) | BBIO |  | scheduled | "- BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, with Priority Review." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm)) |
| February 4, 2027 | [TRUSELTIQ® (infigratinib) PDUFA date](https://sec-api.dev/pdufa/infigratinib) | BBIO |  | scheduled | "- Oral infigratinib for achondroplasia has a February 4, 2027 PDUFA date, with Priority Review." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm)) |
| May 8, 2027 | [Encaleret PDUFA date](https://sec-api.dev/pdufa/encaleret) | BBIO |  | scheduled | "Encaleret for ADH1 PDUFA date set for May 8, 2027, with Priority Review; MAA submitted to EMA U.S. launch upon FDA approval" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm)) |
| 2H 2027 | [Encaleret PDUFA date](https://sec-api.dev/pdufa/encaleret) | BBIO |  | scheduled | "- Encaleret for ADH1 has a May 8, 2027 PDUFA date, with Priority Review, and the MAA is under EMA review with potential EU approval in the second half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm)) |
| late 2027 | [TRUSELTIQ® (infigratinib) topline data readout](https://sec-api.dev/pdufa/infigratinib) | BBIO |  | scheduled | "- The oral encaleret and oral infigratinib franchises continue to expand beyond their first indications: RECLAIM-HP in chronic hypoparathyroidism has begun screening patients with topline data anticipated in late 2027 or early 2028, CALIBRATE-PEDS in pediatric ADH1 has completed enrollment in its first cohort, and a Phase 2 update in hypochondroplasia is expected in the second half of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260630xex991.htm)) |
| early 2028 | [Encaleret topline data readout](https://sec-api.dev/pdufa/encaleret) | BBIO |  | scheduled | "Encaleret for chronic hypoparathyroidism First participant dosed in RECLAIM-HP, registrational Phase 3 study Topline data anticipated early 2028" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm)) |

## Drugs

- [Attruby (acoramidis)](https://sec-api.dev/pdufa/acoramidis): transthyretin amyloid cardiomyopathy, attr-cm, a progressive fatal disease presenting, with attr-cm to reduce cardiovascular death and cardiovascular-related hospitalization, To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis
- [Beyonttra (beyonttra)](https://sec-api.dev/pdufa/beyonttra): 
- [Encaleret](https://sec-api.dev/pdufa/encaleret): adh1, the efficacy, safety, individuals living with autosomal dominant hypocalcemia type 1, chronic hypoparathyroidism in 2026
- [TRUSELTIQ® (infigratinib)](https://sec-api.dev/pdufa/infigratinib): children with achondroplasia, achondroplasia, the efficacy, safety
- [Ribitol](https://sec-api.dev/pdufa/ribitol): lgmd2i/r9, with topline data readout

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/bbio/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BBIO catalysts: BridgeBio Pharma, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/bbio/catalysts

```bibtex
@misc{secapidev_companies_bbio_catalysts_20261116,
  title        = {BBIO catalysts: BridgeBio Pharma, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/bbio/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_bbio_catalysts_20261116","title":"BBIO catalysts: BridgeBio Pharma, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/bbio/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
